BVTI is going to change the way we practice medicine. this is the first and only "patient specific" form of treating a major debilitating disease. their proprietary technology will be basis for how we move forward to treat any and all forms of diseases. bvti is a wholly owned subsidiary of ABPIQ. the only reason this stock is trading the way it is, is because of the "q" behind that ticker. which according to the recent pr and street chatter, they will be emerging with current shareholder intact. that and the stellar phase 3 results, named patient basis in eu, orphan drug status (which means the fda loves this treatment)and impending fda approval, we'll have two $30 stocks.!!!! buy buy buy ABPIQ BVTI
